Regulation of glucose metabolism using anti-CGRP antibodies
AssigneeH. Lundbeck A/S
InventorsBrian Baker, Jeffrey T.L. Smith, John Latham
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods for the prevention or treatment of metabolic disorders. In exemplary embodiments, methods of administering an anti-CGRP antibody are provided, optionally in combination with a second agent, wherein peripheral and/or hepatic glucose utilization is increased, thereby preventing or treating diseases and disorders associated with insulin resistance. Compositions comprising an anti-CGRP antibody are also provided, optionally in combination with a second agent, which are suitable for administration to increase peripheral and/or hepatic glucose utilization and thereby prevent or treat diseases and disorders associated with insulin resistance.
Claims20
A method of decreasing insulin resistance in a subject in need thereof, comprising administrating an effective amount of (I) a composition comprising an anti-human CGRP antibody or antigen-binding antibody fragment and (II) a composition comprising biguanide to said subject,
- wherein said antibody or antigen-binding antibody fragment comprises (i) a VL chain comprising CDR1, CDR2 and CDR3 polypeptides having the amino acid sequences of SEQ ID NOS:
- 55, 56 and 57, respectively;
- and (ii) a VH chain comprising complementarity CDR1, CDR2 and CDR3 polypeptides having the amino acid sequences of SEQ ID NOS:
- 58, 59 and 60, respectively,
- and wherein the subject is diagnosed with prediabetes and/or exhibits one or more of:
- (a) fasting blood glucose level of between 100 mg/dl and 125 mg/dL;
- (b) blood sugar level of between 140 mg/dL and 199 mg/dl two hours after ingesting a 75 g glucose solution or a glucose solution of 1.75 g of glucose per kg of body weight, to a maximum dose of 75 g;
- and/or (c) glycated hemoglobin of between 5.7 percent and 6.4 percent.
A method of reducing insulin resistance in a subject in need thereof, comprising administering an effective amount of a composition comprising an anti-human CGRP antibody or antigen-binding antibody fragment to said subject,
- wherein said antibody or antigen-binding antibody fragment comprises (i) a VL chain comprising CDR1, CDR2 and CDR3 polypeptides having the amino acid sequences of SEQ ID NOS:
- 55, 56 and 57, respectively;
- and (ii) a VH chain comprising complementarity CDR1, CDR2 and CDR3 polypeptides having the amino acid sequences of SEQ ID NOS:
- 58, 59 and 60, respectively,
- and wherein the subject is diagnosed with prediabetes and/or exhibits one or more of:
- (a) fasting blood glucose level of between 100 mg/dl and 125 mg/dL;
- (b) blood sugar level of between 140 mg/dl and 199 mg/dl two hours after ingesting a 75 g glucose solution or a glucose solution of 1.75 g of glucose per kg of body weight, to a maximum dose of 75 g;
- and/or (c) glycated hemoglobin of between 5.7 percent and 6.4 percent.
Dependencies are inferred from the claim text.